Goldfinch Bio to Present at the 2021 Wedbush PacGrow Healthcare Virtual Conference


CAMBRIDGE, Mass. – August 3, 2021 – Goldfinch Bio, a clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced that Anthony Johnson, M.D., President and Chief Executive Officer of Goldfinch Bio, will participate in a panel discussion, Casino Re-nal Part 1 – Novel Mechanisms in Renal Disorders, at the Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 10, 2021 at 3:30 p.m. ET.

About Goldfinch Bio

 Goldfinch Bio, Inc. is a clinical stage biotechnology company focused on delivering disease-modifying precision medicines that bring hope and renewed quality of life to people living with kidney diseases. We aspire to save kidneys and end dialysis. Our precision medicine product engine allows us to discover and validate novel targets aimed at understanding the molecular and phenotypic heterogeneity in diverse kidney disease patient populations to identify subsets most likely to respond to our treatments. We have a robust pipeline of novel, precision medicine product candidates targeting kidney diseases with significant unmet need, including two clinical-stage assets. In 2020, Goldfinch Bio was named one of Fierce Biotech’s “Fierce 15” companies. Visit us at to learn more.

Goldfinch Bio Contacts:

Investors: Hannah Deresiewicz
Stern Investor Relations, Inc.

Media: Liz Melone